U
Vyant Bio, Inc.
VYNT
OTC PK
D
Sell
9/24/2024Upgraded
Vyant Bio, Inc. (VYNT) was upgraded to D- from E+ on 9/24/2024 due to a noticeable increase in the total return index, volatility index and growth index. Operating cash flow increased 67.75% from -$5.61M to -$1.81M, earnings per share increased from -$0.7169 to -$0.2568, and EBIT increased 62.12% from -$4.4M to -$1.67M.
Vyant Bio, Inc. (VYNT) was upgraded to D- from E+ on 9/24/2024 due to a noticeable increase in the total return index, volatility index and growth index. Operating cash flow increased 67.75% from -$5.61M to -$1.81M, earnings per share increased from -$0.7169 to -$0.2568, and EBIT increased 62.12% from -$4.4M to -$1.67M.
E
Sell
3/14/2023Downgrade
Vyant Bio, Inc. (VYNT) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
Vyant Bio, Inc. (VYNT) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Vyant Bio, Inc. (VYNT) was upgraded to D- from E+ on 02/23/2023.
Vyant Bio, Inc. (VYNT) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Vyant Bio, Inc. (VYNT) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Vyant Bio, Inc. (VYNT) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
12/27/2022Downgrade
Vyant Bio, Inc. (VYNT) was downgraded to D- from D on 12/27/2022 due to a decline in the volatility index.
Vyant Bio, Inc. (VYNT) was downgraded to D- from D on 12/27/2022 due to a decline in the volatility index.
D
Sell
12/9/2022Upgraded
Vyant Bio, Inc. (VYNT) was upgraded to D from D- on 12/9/2022 due to an increase in the growth index and valuation index. Operating cash flow increased 45.86% from -$4.16M to -$2.25M, earnings per share increased from -$0.9868 to -$0.5887, and EBIT increased 15.11% from -$4.34M to -$3.68M.
Vyant Bio, Inc. (VYNT) was upgraded to D from D- on 12/9/2022 due to an increase in the growth index and valuation index. Operating cash flow increased 45.86% from -$4.16M to -$2.25M, earnings per share increased from -$0.9868 to -$0.5887, and EBIT increased 15.11% from -$4.34M to -$3.68M.
D
Sell
7/20/2022Downgrade
Vyant Bio, Inc. (VYNT) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and total return index.
Vyant Bio, Inc. (VYNT) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and total return index.
D
Sell
7/1/2022Upgraded
Vyant Bio, Inc. (VYNT) was upgraded to D from D- on 7/1/2022 due to an increase in the volatility index and total return index.
Vyant Bio, Inc. (VYNT) was upgraded to D from D- on 7/1/2022 due to an increase in the volatility index and total return index.
D
Sell
6/13/2022Downgrade
Vyant Bio, Inc. (VYNT) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index and valuation index.
Vyant Bio, Inc. (VYNT) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index and valuation index.
D
Sell
5/25/2022Upgraded
Vyant Bio, Inc. (VYNT) was upgraded to D from D- on 5/25/2022 due to an increase in the volatility index and valuation index.
Vyant Bio, Inc. (VYNT) was upgraded to D from D- on 5/25/2022 due to an increase in the volatility index and valuation index.
D
Sell
5/20/2022Upgraded
Vyant Bio, Inc. (VYNT) was upgraded to D- from E+ on 5/20/2022 due to a substantial increase in the growth index. Total revenue increased 112.08% from -$2.51M to $303, and earnings per share increased from -$1.0213 to -$0.3158.
Vyant Bio, Inc. (VYNT) was upgraded to D- from E+ on 5/20/2022 due to a substantial increase in the growth index. Total revenue increased 112.08% from -$2.51M to $303, and earnings per share increased from -$1.0213 to -$0.3158.
E
Sell
4/18/2022Downgrade
Vyant Bio, Inc. (VYNT) was downgraded to E+ from D- on 4/18/2022 due to a major decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.1539 to -$1.0244, total revenue declined 267.8% from $1.51M to -$2.53M, and the quick ratio declined from 5.22 to 3.87.
Vyant Bio, Inc. (VYNT) was downgraded to E+ from D- on 4/18/2022 due to a major decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.1539 to -$1.0244, total revenue declined 267.8% from $1.51M to -$2.53M, and the quick ratio declined from 5.22 to 3.87.
D
Sell
1/3/2022Upgraded
Vyant Bio, Inc. (VYNT) was upgraded to D- from E on 1/3/2022 due to a large increase in the solvency index and volatility index.
Vyant Bio, Inc. (VYNT) was upgraded to D- from E on 1/3/2022 due to a large increase in the solvency index and volatility index.
E
Sell
10/1/2021Upgraded
Vyant Bio, Inc. (VYNT) was upgraded to E from E- on 10/1/2021 due to a noticeable increase in the growth index and solvency index. Total revenue increased 777.03% from $222 to $1.95M, earnings per share increased from -$2.3134 to -$0.1444, and the quick ratio increased from 4.37 to 5.98.
Vyant Bio, Inc. (VYNT) was upgraded to E from E- on 10/1/2021 due to a noticeable increase in the growth index and solvency index. Total revenue increased 777.03% from $222 to $1.95M, earnings per share increased from -$2.3134 to -$0.1444, and the quick ratio increased from 4.37 to 5.98.
E
Sell
6/25/2021None
Vyant Bio, Inc. (VYNT) was downgraded to E- from U on 06/25/2021.
Vyant Bio, Inc. (VYNT) was downgraded to E- from U on 06/25/2021.
